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Abstract
The mesolimbic dopaminergic system is widely recognized to be critical to the neurobiology of cocaine reward and addiction. The
neuronal protein, a-synuclein, is an important regulator in dopaminergic transmission. It interacts with the dopamine transporter, and
regulates dopaminergic content, neurotransmission and synaptic strength of dopaminergic neurons. Alpha-synuclein levels are
elevated in midbrain dopamine neurons of chronic cocaine abusers, and its expression is increased in psychostimulant-treated
animals [M.S. Brenz-Verca et al. (2003) J. Neurosci., 18, 1923–1938]. This suggests a role for a-synuclein in psychostimulant-
induced behavioural effects. To investigate this hypothesis, we tested the effect of stimulation and silencing of a-synuclein expression
in the nucleus accumbens (NAcc) on two cocaine-induced behavioural effects in the rat. For this purpose, animals were administered
with lentiviruses driving a-synuclein overexpression under the control of a doxycycline regulatable promoter and ⁄ or with three
lentiviruses expressing target-speciﬁc siRNAs, aimed at silencing a-synuclein mRNA expression. Animals were then tested for
cocaine-induced locomotion (15 mg ⁄ kg i.p.) or cocaine-induced intravenous self-administration (SA; 0.7 mg ⁄ kg, 1 h ⁄ day).
Overexpression of a-synuclein in the NAcc induced a 45% increase in locomotor activity and a 1.9-fold increase of cocaine SA,
which could be abolished when the same animal was fed doxycycline. Furthermore, local inhibition of a-synuclein in the NAcc
resulted in signiﬁcant hypolocomotion activity and a decrease in SA. Our results demonstrate that a-synuclein is able to modulate
cocaine-induced behavioural effects. This suggests that targeting a-synuclein function could provide new therapeutic strategies to
treat cocaine abuse, for which there is no available treatment.
Introduction
Drug addiction is a chronic illness that remains a major public heath
problem. Among drugs of abuse, cocaine is one of the most addictive
substances in use today. It binds to the dopamine transporter (DAT)
and blocks the presynaptic uptake of dopamine (DA), mediating the
behavioural and reinforcing effects that contribute to its abuse liability.
Analysis of the DAT-binding sites shows an upregulation in post
mortem brains of cocaine addicts and in acutely abstinent cocaine-
dependent individuals (Lee et al., 2001; Mash et al., 2002). Therefore,
long-term cocaine abuse leads to neuroadaptive changes in DA
homeostasis and in the mesolimbic dopaminergic system, the critical
pathway mediating addiction to psychostimulant and reinforcement.
The synaptic protein, a-synuclein, is an important regulator in
dopaminergic transmission (Abeliovich et al., 2000; Mosharov et al.,
2006). Synucleins are small, soluble proteins expressed primarily in
neural tissue and in certain tumours. The family includes three known
proteins: a-synuclein, b-synuclein and c-synuclein (George, 2001; Li
et al., 2002). a-Synuclein plays a role on synaptic vesicular transport
and synaptic plasticity (Bennett et al., 1999; Murphy et al., 2000), and
has a fundamental function in the genesis of neurodegenerative
disorders (Cooper et al., 2006). It is a major component of Lewy body
in sporadic forms of Parkinson’s disease, and its overexpression is
implicated in the aetiology of Parkinson’s and Alzheimer’s diseases
(Lotharius & Brundin, 2002). Two mutant forms (A53T and A30P) are
linked to the familiar form of Parkinson’s disease (Polymeropoulos
et al., 1997; Kruger et al., 1998; George, 2001; Goedert, 2001).
Furthermore, it is highly expressed in dopaminergic neurons (Abelio-
vich et al., 2000; Perez & Hastings, 2004; Yavich et al., 2004) and is
involved in DA homeostasis, downregulating the activity of tyrosine
hydroxylase and other DA synthesis genes, such as GTP cyclohydro-
lase (Sidhu et al., 2004a). a-Synuclein also binds to the DAT and
serotonin transporters, and affects their activities and their recruitment
to the plasma membrane (Wersinger & Sidhu, 2003, 2005; Wersinger
et al., 2003, 2006). The shuttling of DAT to and away from the plasma
membrane is modiﬁed by the action of a-synuclein, thereby changing
the efﬁciency of DA uptake at the nerve terminals (Sidhu et al.,
2004b).
We have described a- and c-synuclein overexpression in the
mesolimbic dopaminergic pathway upon psychostimulants (Brenz-
Verca et al., 2003). Furthermore, an overexpression of a-synuclein in
DA neurons is observed in cocaine abusers (Mash et al., 2003) or
following methamphetamine administration (Maucelli et al., 2006).
a-Synuclein protein was increased in striatal synaptosomes from
cocaine users compared with age-matched drug-free controls (Yujing
et al., 2005). On the other hand, an increase in expression of
a-synuclein mRNA in alcohol-dependent patients within the with-
drawal state has been observed and has been associated with an
increase in alcohol craving (Weiss et al., 1993; Liang et al., 2003;
Bonsch et al., 2004, 2005). Interestingly, a-synuclein and DA
metabolism play convergent roles in nigrostriatal toxicity (Fornai
et al., 2006), and a-synuclein levels are elevated in midbrain DA
neurons of chronic cocaine abusers (Mash et al., 2003) and are
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associated with methamphetamine psychosis and dependence
(Kobayashi et al., 2004), whereas a-synuclein levels are signiﬁcantly
increased in the amygdala and striatum ⁄ accumbens (but not in the
mesencephalon) of morphine-withdrawn mice (Ziolkowska et al.,
2005). Taken together all these ﬁndings suggest that a-synuclein plays
a key role in addiction, regulating the DA-signalling pathway.
Co-ordinate transcriptional regulation of DA synthesis genes by
a-synuclein has been described (Baptista et al., 2003).
The aim of the present study was to investigate the role of
a-synuclein in the rewarding effects of chronic cocaine administration.
For this purpose, a lentivirus driving the rat a-synuclein overexpres-
sion under the control of a tetracycline regulatable promoter was
constructed. Furthermore, three lentiviruses expressing a-synuclein-
targeted siRNAs, aimed at silencing a-synuclein mRNA expression,
were also constructed. These viruses were tested in vitro and served
for in vivo gene transfer, by means of stereotaxic injections into the
nucleus accumbens (NAcc) of rat brains. The impact of a-synuclein
expression on chronic cocaine administration was assessed, using
locomotor activity and self-administration (SA) paradigms. Overex-
pression of a-synuclein in the NAcc induced a 45% increase in
locomotor activity and a 1.9-fold increase of cocaine SA, which could
be abolished when the same animal was fed doxycycline. Further-
more, local inhibition of a-synuclein in the NAcc ) efﬁciently
achieved in vivo using lentiviruses expressing a-synuclein-speciﬁc
siRNAs ) resulted in signiﬁcant hypolocomotion activity and a
decrease in SA.
Materials and methods
Ex vivo methods
Lentivirus constructions
Construction of Lenti-a-Synuclein (Lenti-aSyn). The a-synuclein
DNA (GenBank accession no. AF007758) was polymerase chain
reaction (PCR) ampliﬁed using the pGEMT-rat-Alpha-Synuclein as
template and the following primers: 5¢-CGC GGA TCC GCG ATG
GAT GTG TTC ATG AAA-3¢ and 5¢-CCG CTC GAG CGG TTA
ATG ATG ATG ATG ATG ATG GGC TTC AGG CTC ATA GTC
T-3¢. The forward primer contains a BamH-I restriction site followed
by the 5¢ rat a-synuclein DNA-speciﬁc sequence; the reverse primer
contains the 3¢ rat a-synuclein DNA-speciﬁc sequence, the 6-Histidine
epitope sequence (in bold), a stop codon and a Xho-I restriction site.
The PCR product was digested with BamH-I and Xho-I, and cloned
into BamH-I ⁄ Xho-I restriction sites into pTK431 (Bahi et al., 2005a)
that expresses the gene of interest under control of a Tet-Off promotor.
The green ﬂuorescent protein (GFP) expression vector pTK433 (Bahi
et al., 2004a,b) was used as a control vector.
Construction of Lenti-a-synuclein-siRNAs (Lenti-aSyn-siRNA). To
silence a-synuclein expression in vitro and in vivo, three targets were
designed, according to the a-synuclein mRNA sequence. The
following targets within the a-synuclein sequence were selected,
based on Hannon’s design criterion (http://katahdin.cshl.org:9331/
RNAi/html/rnai.html): ﬁrst target: bp 36–52; second target: bp 305–
320; third target: bp 406–423. To each oligo, a Xho-I restriction site
was added at 3¢, and a U6-3¢-speciﬁc 10mer at 5¢. Using the pSilencer
1.0-U6 (Ambion, UK) as a template and a U6 promoter-speciﬁc
forward primer containing BamH-I restriction site (5¢-GCG GAT CCC
GCT CTA GAA CTA GTG C-3¢), each siRNA target was added to the
mouse U6 promoter by PCR, using the following PCR program: 120 s
at 94 C (initial denaturation) followed by 35 cycles (45 s at 94 C,
45 s at 64 C and 45 s at 72 C) in 4% dimethyl sulphoxide (Sigma,
Switzerland). The PCR product was digested with BamH-I and Xho-I,
cloned into similar sites into pTK431, and sequenced to verify the
integrity of each construct.
Lentivirus production
The vector plasmids (either pTK431-a-Synuclein, pTK433-GFP or
pTK431-U6-a-Syn-siRNAs), together with the packaging construct
plasmid pÆNRF and the envelope plasmid pMDG-VSV-G were
co-transfected into human embryonic kidney (HEK)293T cells to
produce the viral particles (Bahi et al., 2004a,b). The viral titres were
determined by p24 antigen measurements (KPL, USA). For the in vivo
experiments, the different viral stocks were matched for viral particle
content and used at 0.2 mg ⁄mL of p24.
In vitro a-synuclein assays
The efﬁciency of the Lenti-aSyn was tested in vitro by infection of
HEK293T cells. 1 · 105 HEK293T cells were plated. The next day,
lentiviruses stocks were mixed with 4 lg ⁄mL Polybrene (Sigma,
Switzerland) with or without 30 ng ⁄mL doxycycline (Sigma), incu-
bated for 30 min at room temperature, added to the cells and incubated
at 37 C. After 24 h the medium was replaced with normal growth
medium (with or without 30 ng ⁄mL doxycycline) and cells were left
for a further 48 h. Cells were then collected and used for total RNA
isolation (for real-time PCR) or for total protein isolation (Western
blot). Infections with the different lentiviruses were done as follows:
(a) doxycycline regulation: cells were co-infected using 0, 2, 4 or 8 lL
of Lenti-aSyn stock, and one part of the cells was incubated in the
presence of 30 ng ⁄mL doxycycline and the other part without
doxycycline; (b) in vitro silencing of a-synuclein: cells were infected
with 4 lL of Lenti-aSyn stock, either alone or together with 2 lL of
Lenti-aSyn-siRNAT1, 2 lL of Lenti-aSyn-siRNAT2, 2 lL of Lenti-
aSyn-siRNAT3, or with 2 or 4 lL of all three targets together (mix of
Lenti-aSyn-siRNA T1, Lenti-aSyn-siRNA T2 and Lenti-aSyn-siRNA
T3).
Quantitative real-time PCR and quantiﬁcation of a-synuclein
transcripts
For quantitative real-time PCR, primer sets for rat a-synuclein,
glyceralaldehyde-3-phosphate-dehydrogenase (GAPDH) or b-actin
were designed to amplify 100- to 200-bp products, using PRIMER3
software: (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_http://
www.cgi). The following speciﬁc primer pairs were used: a-synuclein:
5¢-GCG TCC TCT ATG TAG CTT CCA-3¢ and 3¢-AGC AGC AAT
GTT CCC AGC; GAPDH: 5¢-ATG ACT CTA CCC ACG GCA AG-3¢
and 5¢-CAT ACT CAG CAC CAG CAT CAC-3¢; b-actin: 5¢-AGC
CAT GTA CGT AGC CAT CC-3¢ and 5¢-CTC TCA GCT GTG GTG
GTG AA-3¢. GAPDH and b-actin were used as endogenous controls
for normalization. No difference in expression was observed between
these two genes in all quantiﬁcations.
Total RNA was extracted from the HEK293T cells (for in vitro
quantiﬁcation) and from brains of cocaine-treated animals (for in vivo
quantiﬁcation) using TRIzol Reagent (Invitrogen), including an
RNase-free DNase step. RNA was quantiﬁed by spectrophotometry,
and its integrity veriﬁed by agarose gel electrophoresis as visualized
with ethidium bromide staining. First-strand cDNA was generated
from 2 lg total RNA and Oligo(dT12)18)-primer with the M-MLV
reverse transcription kit (Invitrogen) in a total volume of 20 lL. The
reaction product was used for quantitative real-time PCR using the
real-time PCR iCycler (Bio-Rad, Switzerland). cDNA preparation
(2 lL), 0.5 lm of forward and reverse primers, and 10 lL of IQ
SYBR Green Supermix (Biorad) in a total volume of 20 lL were
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applied, and PCR was performed as follows: 3 min at 95 C (initial
denaturation); 20 C ⁄ s temperature transition rate up to 95 C for
45 s, 62 C for 45 s, repeated 40 times (ampliﬁcation). The PCR
reaction was evaluated by melting curve analysis and by checking the
PCR products on 2% agarose gel.
The PCR cycle number at which each assay target reached the
threshold detection line was determined (‘threshold cycles’, Ct value).
The Ct of each gene was normalized against that of GAPDH or b-actin.
To determine the linearity and detection limit of the assay, cDNA
samples were ampliﬁed for successive 10-fold dilutions in a series of
real-time PCRs, using a duplicate assay on each dilution, so that the
correlation coefﬁcient could be calculated from the standard curve of Ct
values. Comparisons were made between cocaine and saline groups,
and signiﬁcance was calculated using two-tailed Student’s t-test, and
the level of statistical signiﬁcance was set at P < 0.05. Data were
expressed as means ± SEM. The ÆCt for each candidate was calculated
as: ÆCt ¼ [Ct (candidate) ) Ct (GAPDH or b-actin)].
The relative abundance of each target in each protocol can be
calculated as the ratio between treated and untreated samples (Bahi &
Dreyer, 2004; Bahi et al., 2004b).
Western blotting
Rat NAcc (150–200 mg) or transfected HEK293T cells were homog-
enized in buffer (in mm: Tris, 50, pH 7.5; NaCl, 120; CaCl2, 1.5;
MgCl2, 5; KCl, 5; EDTA, 5) with a protease inhibitor mixture (Sigma,
St Louis, MO, USA; 1 mL ⁄ 20 g of tissue). Homogenates were
solubilized with 1% digitonin, followed by the addition of secondary
solubilization buffer [in mm: Tris, 50, pH 7.6; NaCl, 150; 1%
Nonidet-P40; 0.5% sodium deoxycholate; EDTA, 2; sodium ortho-
vanadate, 1; phenylmethylsulphonyl ﬂuoride (PMSF), 1; 1% Triton X-
100], and centrifuged at 10 000 g at 4 C for 15 min. Solubilized
extracts were subjected to sodium dodecyl sulphate–polyacrylamide
gel electrophoresis (SDS–PAGE). Blots were blocked with 5% non-fat
dried milk dissolved in Tris-Buffered Saline Tween-20 (TBST)
(in mm: Tris, 10; NaCl, 150; 0.1% Tween-20) for 1 h at room
temperature, and incubated with primary antibodies for either 6-His
(1 : 2000, ABCam, ab5000) or a-synuclein (1 : 1000, ABCam,
ab1904) for 10–12 h at 4 C. Blots were washed three times with
TBST and incubated for 1 h with the peroxidase-conjugated secondary
antibody solution. Proteins were then visualized using enhanced
chemiluminescence (Millipore). Membranes were washed for 30 min
in TBST and placed in stripping solution (glycine-HCl 25 mm,
pH 2.0, 1% SDS) for 30 min and used as described above for b-actin
detection. (1 : 4000, Sigma). Signals were detected with a Fluorchem
tm 8900 apparatus (Alpha Innotech), and the TIFF pictures were
quantiﬁed with the multianalyst software (Biorad).
Immunohistochemistry
For immunohistochemistry assays, rats were decapitated. Brains were
quickly removed from the skull, immediately frozen in isopentane (at
)30 C for 3 min) and kept at )25 C. Coronal sections were cut at
14 lm in a cryostat and placed on gelatinized glass slides, air-dried
at room temperature for 20 min and kept at )25 C until further
processing.
Brain sections were ﬁxed for 10 min in cold acetone and washed
three times in 1 · phosphate-buffered saline (PBS). Non-binding sites
were blocked by incubating slices for 1 h in 1 · PBS containing 1%
bovine serum albumin, 1% Triton X-100 and 3% normal goat serum.
Sections were then incubated overnight at 4 C with primary
antibodies speciﬁcally against either a-synuclein (mouse
anti-a-synuclein antibody, ABCam ab1904, 1 : 5000), 6-His
(mouse anti-histidine antibody, MCA1396, Serotec, 1 : 5000), NeuN
(mouse anti-neuronal-nuclei, MAB 377, Chemicon, 1 : 5000) or
synaptophysin (mouse anti-synaptophysin, Chemicon, MAB329,
1 : 1000). Antibodies were diluted in 1 · PBS containing 0.1% Triton
X-100 and 1% normal goat serum. Thereafter, slices were washed three
times in 1 · PBS, and incubated for 2 h in the secondary antibody
(Texas red-conjugated goat anti-mouse immunoglobulin G, 1 : 500) or
(FITC-conjugated goat anti-mouse IgG, 1 : 500) in 1 · PBS containing
0.1% Triton X-100. The sections were coverslipped with a medium
containing glycerol in PBS (AF1 mounting solution, Citiﬂuor).
Negative controls included omission or substitution of primary
antibodies.
Fluorescence microscopy. To observe the stained sections, a multi-
ﬂuorescence microscope (Axioplan 2 imaging; Zeiss) was used with a
40 · or 100 · objective. Fluorophores (FITC and Texas red) used
were detected with the appropriate detecting systems (HAL 100).
FITC was excited at 495 nm and was detected through a light path
ranging 510–550 nm. Texas red was exited at 570 nm and was
detected through a light path ranging 600–660 nm. Stained sections
were visualized, photographed using a multichannel camera (Axio-
cam, Zeiss) combined with acquisition software (Axiovision system
3.1) and recorded on CD.
In vivo methods
Animal handling and behavioural analysis
Animals used in this experiment were male Wistar rats weighing 250–
280 g. All animal experiments were carried out in accordance with the
guidelines and regulations for Animal Experimentation, BAG, Bern,
Switzerland. The animals were housed four per cage, in clear plastic
cages with wire grid lids. Access to food and water was unrestricted.
The animals were kept in the animal facility maintained on a 12 h
light : dark cycle (lights off at 07.00 h). At the end of each in vivo
experiment, the animals were decapitated, and brains removed for
analysis.
For doxycycline treatment, animals were maintained with 0.02%
doxycycline (Sigma) and 5% sucrose supplemented in water. During
the gene overexpression period, animals were maintained only with
5% sucrose.
Stereotaxic surgery
Stereotaxic surgery and injection of the lentiviral vector were
performed according to previous publications (Bahi et al., 2004a,b).
Rats were anesthetized with ketamine-xylazine (10 mg ⁄ kg and
0.1 mg ⁄ kg) administered i.p. Animals were bilaterally injected into
the NAcc with 2 lL of concentrated lentiviral stock (0.2 mg ⁄mL of
p24, corresponding to 8 · 109 IU ⁄mL). The injections were per-
formed bilaterally at the following coordinates, as calculated from
bregma and the dura mera: anterior +1.4; lateral ± 1.2; ventral )6.8
(Paxinos & Watson, 1998).
Intravenous surgery
Wistar rats (250–280 g) were individually housed under a constant
12 h light : dark cycle (lights off at 07.00 h) with free access to food
and water. Under anaesthesia, a SILASTIC catheter (15 lL dead
volume) was inserted in the external jugular vein. Rats were
anaesthetized with a cocktail mixture of ketamine (10 mg ⁄ kg) and
xylazine HCl (0.1 mg ⁄ kg) administered i.p. in a volume of
1 mL ⁄ kg. The surgical procedure consisted of making an incision
between the breastbone and the clavicle to expose the jugular vein.
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The catheter was inserted into the jugular vein and secured with
sutures. The catheter was then passed under the skin and ﬁxed in the
mid-scapular region. For the ﬁrst 3 days after surgery, the catheters
were ﬂushed daily with 0.1 mL of saline mixed with heparin
(100 U ⁄mL) and gentamicin (1 mg ⁄ kg). Thereafter, the catheters
were ﬂushed with a saline–heparin mixture after each session.
Standard operant chambers (Coulbourn Instruments, Allentown, PA,
USA) housed in ventilated sound-attenuating cubicles (Coulbourn
Instruments) with fans to mask outside noise were utilized for the
SA. One response lever with three ‘cue’ lights above was located on
one wall of each chamber. Close to the lever was a recessed food
receptacle into which food pellets (45 mg each; Bio-Serv, French-
town, NJ, USA) could be dispensed from a pellet dispenser. A house
light was also located within the chamber. These chambers were
equipped with syringe pump systems, which consisted of an infusion
pump (Razel model A-99; Stamford, CT, USA) with a 10-mL plastic
syringe connected by a single-channel 22-gauge swivel (Instech
Laboratories; Plymouth Meeting, PA, USA) with Teﬂon tubing. The
tubing could be connected to the animal’s catheter system in order to
deliver cocaine solution. Graphic State Notation (Coulbourn Instru-
ments) was used to program experimental parameters (e.g. schedules of
reinforcements, time periods, etc.), and tabulate and store session data.
Procedures
Experiment 1: cocaine-induced locomotion. Four groups of animals
(n ¼ 6) were prepared: one group was stereotaxically injected with
2 lL of Lenti-GFP (controls); one group was stereotaxically injected
with 2 lL of Lenti-aSyn; a third group was injected with 2 lL of a
mix of all three Lenti-aSyn-siRNA; and the fourth group was injected
with 2 lL Lenti-aSyn together with 2 mL of a mix of the three Lenti-
aSyn-siRNA. Seven)12 days after stereotaxic surgery, locomotor
activity was monitored in daily sessions over 3 · 5 days in
43.2 · 43.2 cm MED-OFA-RS cages (MED Associates, USA) during
the dark cycle, according to previously published procedures (Bahi
et al., 2004a,b). Animals were daily injected cocaine i.p. and were fed
without doxycycline for 5 days (Session A), then fed doxycycline for
7 days (Session B), and ﬁnally fed without doxycycline for 7 days
(Session C). Locomotor activity was recorded on Days 1–5, 8–12 and
15–19; over the 2-day periods between sessions ) necessary for full
doxycycline-mediated switch of ectopic a-synuclein expression ) no
measurements were performed (Table 1). Prior to each locomotor
activity measurements, the animal was injected with 0.9% saline, and
placed into the activity-monitoring cage for a 15 min baseline. After
this 15-min period, the session automatically paused for a few seconds
and, during this interval, each subject received cocaine-HCl (Sigma,
15 mg ⁄ kg, i.p.) and was then placed back into the locomotor activity-
monitoring cage for a further 60 min. Statistical evaluation of
behavioural analysis was performed according to previous publi-
cations (see Bahi et al., 2004a,b). At the end of the third session
(Session C) half of the animals were killed. The other half were
switched back on doxycycline for 48 h then killed. All animals were
killed by decapitation. During this switch period, animals were still
daily administered cocaine and, as for the other group, were killed
24 h after the last cocaine injection. Brains were used either for
immunocytochemistry or quantitative real-time PCR.
Two additional groups (n ¼ 8) of naı¨ve animals, one fed doxycy-
cline for 5 days, were also killed and their brains dissected. These
groups received no cocaine and no lentivirus treatment, and their brain
part served as controls for evaluation of cocaine-induced expression
of a-synuclein in other groups in quantitative real-time PCR
measurements.
Experiment 2: cocaine-induced intravenous SA. Prior to surgery, rats
were food-restricted to 85% of free feeding body weight and trained to
lever-press for food reinforcement using a ﬁxed ratio (FR)1 schedule
of reinforcement during 60-min sessions. Training continued until the
animal earned the constant number of reinforcers for two consecutive
days. After this training period and a sufﬁcient time to regain weight
lost during food restriction, the stereotaxic and the intravenous
catheter surgeries were performed at the same time. Four different
groups of animals, stereotaxically injected like in Experiment 1, were
prepared (n ¼ 9). After 7 days of recovery, rats were tested for cocaine
SA. They were placed into the operant chambers, connected to the
catheter ⁄ cannula system, and allowed to SA cocaine during daily 1-h
sessions. Testing started 2 h after lights off. One depression of the active
lever (FR1) resulted in an intravenous infusion of 20 lL of a solution
containing 0.7 mg ⁄ kg of cocaine. The cocaine infusion was delivered
over a 2-s period followed by a 40-s time out. Active lever presses that
were emitted during the infusion time or during the time out period were
tabulated but did not result in any further cocaine delivery. During the
infusion, the house light was turned off, and the cue lights over the active
lever were illuminated. During the time out period the house light was
turned on and the cue lights were switched off. The criterion for
acquisition of cocaine SA was deﬁned by a stable number of self-
infusions over at least three consecutive sessions (± 20%). When
cocaine showed control over behaviour under the FR1 schedule of
reinforcement, the FR requirement was raised to FR2, FR3 and then to
FR5, the schedule used for the remainder of the experiment.
Table 1. Summary of experimental protocol for each group of animals in Experiment 1
Days 1–22:
Sessions
A Switch B Switch C End or switch
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Doxycycline (+ ⁄ –)
Group 1 – – – – – + + + + + + + – – – – – – – – End (n ¼ 4)
Group 2 – – – – – + + + + + + + – – – – – – – + + + End (n ¼ 4)
Group 3 – – – – – + + + + + + + – – – – – – – – End (n ¼ 4)
Group 4 – – – – – + + + + + + + – – – – – – – + + + End (n ¼ 4)
Measurement + + + + + – – + + + + + – – + + + + + – – –
See the Materials and methods section for details. At the end of the experiment the animals were killed and the brains used either for immunocytochemistry or
quantitative real-time PCR.
4
ht
tp
://
do
c.
re
ro
.c
h
As in Experiment 1, half of the animals were killed by decapitation
24 h after the last cocaine SA session, while the remaining (n ¼ 5)
were fed doxycycline for 48 h before being killed. During this switch
period, animals were still daily tested and, as for the other group, were
killed 24 h after the last cocaine SA session. Brains were used either
for immunocytochemistry, Western blot or quantitative real-time PCR
analysis.
In vivo assays of a-synuclein
The efﬁciency of the lentivirus-mediated a-synuclein expression
in vivo was assessed by stereotaxic injection, into the NAcc, of
Lenti-aSyn stock alone in a ﬁrst group of animals, or Lenti-aSyn
together with Lenti-aSyn-siRNAs mix in a second group of animals.
To suppress endogenous a-synuclein expression, a third group of
animals were infected only with 2 lL of Lenti-aSyn-siRNAs mix.
Finally, a control group of animals was injected in the same brain
area with Lenti-GFP. After surgery, animals were left for recovery
for 7 days. At the end of the behavioural analysis (locomotor activity
or SA), some of the animals were killed by decapitation 24 h after
the last cocaine injection, while the remaining animals were fed
doxycycline for 48 h before being killed. During this switch period,
animals were still daily administered cocaine and, as for the other
group, were killed 24 h after the last cocaine injection. Brains were
either homogenized for protein or quantitative real-time PCR
analysis, or dissected out for immunohistochemistry analysis. For
molecular analysis, brains were dissected out and the NAcc, striatum
and ventral tegmental area (VTA) regions were isolated. Tissues
were used for RNA extraction using TRIzol Reagent (Invitrogen) or
for protein extraction.
Statistical analyses
Two-way anova was used to compare both lentiviral and drug
treatment in the presence or absence of doxycycline, using
GraphPad PRISM (V3.0, GraphPad, San Diego, California, USA).
For locomotor activity two-way anova was used, with time as the
within-subject factors and lentiviral treatment as the between-subject
factors followed by Bonferroni post hoc tests. For SA and real-time
PCR analysis, two-way anovas were used with drug treatment
(water vs doxycycline) as the within-subject factors and lentiviral
treatment as the between-subject factors followed by Bonferroni
post hoc tests.
Results
Lentivirus-mediated a-synuclein expression in HEK293T cells
a-Synuclein was cloned into a tetracycline-regulatable lentivirus
system. The lentivirus expressing a-synuclein (Lenti-aSyn) was used
for in vitro assays (see Materials and methods). HEK293T cells were
infected with different amounts of virus (Fig. 1A), and a-synuclein
mRNA was measured by real-time PCR. As shown, Lenti-aSyn
induced a-synuclein gene and protein expression in a dose (titre)-
dependent manner. Using 2, 4 and 8 lL of viral stock, a-synuclein
mRNA increased by 4.7-, 8.8- and 12.6-fold (F6,28 ¼ 32.81,
P < 0.001), respectively. This induction is completely reversible in
the presence of doxycycline, which blocks lentivirus-mediated
a-synuclein overexpression, both at the mRNA (Fig. 1A) and the
protein levels (Fig. 4). For real-time PCR, a-synuclein transcripts
levels were normalized against b-actin used as endogenous control.
GAPDH expression, an endogenous control, is unaffected by lenti-
virus-mediated gene transfer (Fig. 1A and B)
SiRNAs-expressing lentiviruses and a-synuclein silencing
in vitro
In order to knockdown a-synuclein expression, lentivirus-based RNA
interference was used. Three different siRNAs were designed, cloned
into the lentiviral transfer plasmid (Lenti-aSyn-siRNAs T1, T2 and
T3) and their silencing efﬁciency was assessed in vitro in Lenti-aSyn-
infected HEK293T cells (Fig. 1B). Target speciﬁcity was controlled by
co-infections of HEK293T cells with Lenti-GFP. Ninety-six hours
after infection, cells were harvested, total RNA was extracted and
transcripts levels were measured by means of quantitative real-time
PCR using speciﬁc primers for each candidate. All normalizations
were performed against b-actin (no signiﬁcant difference was
observed when GAPDH instead of b-actin was used for normalization,
P > 0.05). Cells co-infected with Lenti-a-Syn were set-up to 100% of
a-synuclein expression level (Fig. 1B; ‘4lL’). When Lenti-GFP was
also added during co-infection no signiﬁcant change of a-synuclein
mRNA levels was observed, yielding 98% of a-synuclein tran-
scripts, vs 100% in controls (data not shown). In contrast, co-infection
with Lenti-aSyn-siRNAs T1, T2 and T3 resulted in drastic
a-synuclein downregulation, yielding 29.1%, 43.1% and 34.2%
residual a-synuclein expression levels, respectively. (Fig. 1B;
F4,20 ¼ 22.70, P < 0.01). Co-infection in the presence of all three
Lenti-aSyn-siRNAs together resulted in 90.8% a-synuclein mRNA
knockdown (Fig. 1B; ‘4 lL + all’, P < 0.01). Under all conditions,
the expression levels of other genes (e.g. GAPDH; Fig. 1B) were not
Fig. 1. Quantiﬁcation of in vitro expression of a-synuclein mRNA in
HEK293T cells using quantitative real-time polymerase chain reaction
(PCR). (A) Dose–response effects of Lenti-aSyn. HEK293T cells were
infected with 0, 2, 4 or 8 lL Lenti-aSyn in culture medium in the presence
or absence of doxycycline (30 ng ⁄mL), as indicated. After 96 h, culture
medium was removed and cells were used for total RNA extraction, cDNA
preparation and quantitative real-time PCR using speciﬁc oligos. Results were
normalized against GAPDH used as endogenous control. Normalized transcript
levels were from cells infected without doxycycline. Control: non-infected
HEK293 cells. *P < 0.05, **P < 0.01 and ***P < 0.005 vs non-infected
cells. (B) Silencing efﬁciency of Lenti-aSyn-siRNAs. HEK293T cells were
infected with 4 lL Lenti-aSyn with or without other viruses, as indicated. After
96 h, culture medium was removed and cells were used for total RNA
extraction, cDNA preparation and quantitative real-time PCR using speciﬁc sets
of primers. Results were normalized vs GAPDH as endogenous control.
**P < 0.05 and ***P < 0.005 vs cells infected with Lenti-aSyn.
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affected by Lenti-aSyn-siRNAs, indicating that the targets are highly
a-synuclein speciﬁc.
Western blot analysis, using either anti-a-synuclein antibody or
anti-6His antibody, showed that protein expression highly correlates
with transcripts levels (Fig. 2). Quantiﬁcation from 6-His-based
Western blots shows that co-infection of Lenti-aSyn with T1, T2 or T3
resulted in 12%, 22% and 3% residual a-synuclein, respectively,
whereas co-infection of Lenti-aSyn with all three Lenti-aSyn-siRNAs
together resulted in < 4% residual a-synuclein (Fig. 2; F6,28 ¼ 23.07,
P < 0.001).
In vivo cocaine-mediated a-synuclein expression and silencing
Four groups of animals (n ¼ 8), stereotaxically injected with different
combinations of lentiviruses, were prepared and behaviour was
measured in three 5-day sessions (locomotor activity or SA, see
Materials and methods, and Table 1). Animals received daily cocaine
injections. During the ﬁrst 5-day session (‘Session A’) animals were
fed without doxycycline during ﬁve consecutive days, and then
switched to the doxycycline regimen for 7 days, but the behavioural
analysis was performed only 2 days after the switch, for ﬁve
consecutive days (‘Session B’). Finally, animals were switched again
without doxycycline and measured 2 days later for ﬁve consecutive
days (‘Session C’). At the end of the behavioural analyses, half of the
animals from each group were killed, the second half of the animals
was fed doxycycline for 48 h (turning off a-synuclein overexpression
in the NAcc), and then killed. After killing, brains were removed,
NAcc tissues were dissected out and used either for total RNA
extraction or Western blot analysis to test lentivirus-mediated and
cocaine-induced a-synuclein expression in vivo.
mRNA expression in vivo
After reverse transcription, mRNA expression levels were measured
by means of quantitative real-time PCR. Data have been normalized
with respect to the control groups that consisted of naı¨ve animals not
receiving cocaine but fed either with or without doxycycline. These
two groups served to assess cocaine-mediated induction of
a-synuclein. Data are shown in Fig. 3.
When animals have been injected with Lenti-GFP, a-synuclein
expression was 3.1 compared with saline-injected control (Fig. 3;
F4,20 ¼ 103.03, P < 0.01), reﬂecting cocaine-mediated induction of
endogenous a-synuclein. Animals of this group switched to doxycy-
cline displayed 2.5-fold cocaine-induced increase in a-synuclein
expression, compared with saline-injected control animals (Fig. 3;
P > 0.05, F4,20 ¼ 103.03), a ratio not signiﬁcantly different from the
corresponding group fed without doxycycline. The ratios of other
targets, e.g. b-actin mRNA, remained unchanged over saline-treated
control animals in both cases.
When animals were injected with only Lenti-aSyn, strong induction
of a-synuclein mRNA expression was observed in the absence of
doxycycline, with a ratio of 12.3 (F4,20 ¼ 103.03, P < 0.001)
compared with saline-treated controls (Fig. 3). This expression level
dropped 3.3-fold with doxycycline, up to a ratio of 3.7 (compared with
naı¨ve controls), equivalent to the ratio observed for GFP-treated
animals (F4,20 ¼ 103.03, P < 0.01). b-Actin mRNA expression was
not affected, and ratios of 1.5 and 1.3, respectively (no doxycy-
cline), and 1.6 and 2.8, respectively (with doxycycline), were
found for cocaine- and saline-treated animals under these conditions
Fig. 2. Expression of a-synuclein in the HEK293T cells. Cells were trans-
fected as in Fig. 1. Proteins were extracted as described in Materials and
methods, to compare a-synuclein expression in different lentivirus infected
cells (control C in left-most column). (A) Immunoblots of a-synuclein
expression. Western blots from gels loaded with 15 lg protein ⁄ lane were
analysed for a-synuclein or 6-histidine expression, and reprobed with anti-b-
actin antibody to compare a-synuclein expression in lentivirus-infected cells.
(B) Semi-quantitative analysis of Western blot signals. a-Synuclein signals
were estimated using multianalyst software and normalized against GAPDH
signal. ***P < 0.001 a-synuclein protein quantiﬁcation vs cells infected with
4 lL Lenti-aSyn; +++P < 0.001 6-histidine quantiﬁcation vs cells infected with
4 lL Lenti-aSyn, two-way anova, Bonferroni post hoc tests.
a b c d e
Fig. 3. In vivo overexpression and silencing of a-synuclein mRNA in the
nucleus accumbens (NAcc) after infection with Lenti-aSyn and ⁄ or Lenti-aSyn-
siRNAs: quantiﬁcation of transcripts by means of quantitative real-time PCR.
Animals (n ¼ 8) were bilaterally injected into the NAcc with either: (a) Lenti-
aSyn alone; (b) Lenti-aSyn combined with a mix of all Lenti-aSyn-siRNAs; (c)
a mix of Lenti-aSyn-siRNAs; or (d) Lenti-green ﬂuorescent protein (GFP); and
(e) untreated animals (as a control). At the end of the behavioural analysis
(locomotor activity), part of the groups used were killed by decapitation 24 h
after the last injection; the NAccs were dissected out and used for total RNA
isolation, cDNA preparation and quantitative real-time PCR using speciﬁc
oligos. Results were normalized against GAPDH. ***Represents points
signiﬁcantly different from Lenti-aSyn-infected rats (***P < 0.001). ## and
###Represent points signiﬁcantly different from Lenti-GFP-injected rats.
(##P < 0.01; ###P < 0.001) Two-way anova, Bonferroni post hoc tests.
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(F4,20 ¼ 103.03, P < 0.01), similar to those observed in the Lenti-
GFP-treated group.
When animals have been injected with Lenti-aSyn together with a
mix of Lenti-aSyn-siRNAs, drastic inhibition of a-synuclein expres-
sion is found in the absence of doxycycline, resulting in a ratio of
1.1 (F4,20 ¼ 103.03, P < 0.01) compared with naı¨ve controls, i.e. at
least 11-fold inhibition (Fig. 3). With doxycycline, complete inhibition
of a-synuclein was found, with ratios 0.01 compared with naı¨ve
controls (F4,20 ¼ 103.03, P < 0.001). Indeed, doxycycline blocks
exogenous, lentivirus-mediated a-synuclein overexpression (but not
endogenously expressed a-synuclein), while silencers also block
endogenous a-synuclein. Under these conditions, the other targets
(b-actin, etc.) were not modiﬁed at all, indicating that Lenti-
aSyn-siRNAs had no effects on their expression levels.
Finally, when animals have been injected with the Lenti-aSyn-
siRNAs only (without Lenti-aSyn), the a-synuclein mRNA expression
level dropped up to 0.007 (P < 0.001) and even to 0.003 with
doxycycline (F4,20 ¼ 103.03, P < 0.001) ) corresponding to full
silencing of endogenous a-synuclein mRNA expression ) whereas
b-actin was not modiﬁed. This value, compared with that observed in
the Lenti-GFP-treated group, indicates that a > 99% knockdown of the
endogenous a-synuclein has been achieved. As described previously
(Bahi et al., 2004a,b, 2005a,b), the use of a mix of three lentivirus
silencers most often warrants optimal gene silencing, as requested for
observation of solid behavioural changes.
Protein expression in vivo
Protein expression was assessed from the NAcc of treated animals
after behavioural analysis (see Table 1). After killings, brains were
dissected out, and the NAccs were used for Western blot analysis
(Fig. 4).
Cocaine induces an approximate 1.8-fold increase in a-synuclein
expression in naı¨ve (control) animals not injected with any lentivirus
(Fig. 4), in agreement with previous publications (Brenz-Verca et al.,
2003). In the absence of doxycycline, Lenti-aSyn-treated animals
display a 7.3-fold higher expression of ectopic a-synuclein after
chronic cocaine treatment (Fig. 4; 100%, P < 0.001, F3,16 ¼ 239.68),
but this expression level is reduced by 70% in the presence of
doxycycline. Animals treated with both Lenti-aSyn and Lenti-aSyn-
siRNAs display 22% and 6% expression in the presence or absence of
doxycycline (P < 0.001, F3,16 ¼ 239.68), compared with the ﬁrst
group (animals treated with Lenti-aSyn only, in the absence of
doxycycline). The remaining a-synuclein expression reﬂects cocaine-
mediated endogenous expression of a-synuclein, which is almost fully
knocked down by Lenti-aSyn-siRNAs, yielding 4–5% expression
only compared with the Lenti-aSyn group and 18% of the control
group only (Fig. 4; F3,16 ¼ 239.68, P < 0.001).
Immunohistochemistry was performed on brains from animals
treated under similar conditions (Fig. 5). Animals treated with Lenti-
aSyn display a very strong overexpression of a-synuclein in the NAcc
(Fig. 5; left panels); under these conditions doxycycline induced a
very large (> 90%) suppression of a-synuclein overexpression in the
NAcc. Animals treated with Lenti-aSyn combined with Lenti-aSyn-
siRNA displayed a strong (> 98%) suppression of a-synuclein,
although some a-synuclein could still be observed (Fig. 5; left-middle
panels) that was almost fully abolished when under doxycycline. In
contrast, animals treated only with Lenti-aSyn-siRNA, silencing
endogenously expressed a-synuclein, display > 99% silencing of
endogenous cocaine-mediated a-synuclein expression. Cocaine-med-
iated a-synuclein expression could be assessed from the control GFP-
treated group and was not affected by doxycycline treatment (Fig. 5;
right panels).
Furthermore, the subcellular localization of a-synuclein has been
determined via double-immunolabelling. NeuN was used as a speciﬁc
marker for neuronal nuclei, and synaptophysin was used to detect
presynaptic vesicles (Supplementary material, Fig. S1). As shown in
Fig. 5, a-synuclein was consistently co-expressed with synaptophysin,
indicating that the protein is found in presynaptic vesicles. Further-
more, double-immunolabelling of a-synuclein and NeuN does not
show a-synuclein co-localization in the nuclear part of the neurons;
under these conditions a-synuclein appears rather expressed in a
neuritic manner. Taken together these results demonstrate that
lentiviral overexpression of a-synuclein results in high protein levels
that could be abolished by doxycycline treatment. Furthermore,
lentiviral-mediated overexpression of a-synuclein leads to increased
protein levels both in neurites and presynaptic vesicles of neuronal
cells (supplementary Fig. S2).
Locomotor activity changes induced upon a-synuclein
expression
Previous work clearly established that GFP overexpression in the
NAcc has no signiﬁcant effect on locomotor activity, compared with
naı¨ve animals (Bahi et al., 2004a,b). For this reason, Lenti-GFP-
treated animals have been used as a control in the behavioural
test (Fig. 6). Animals infected with Lenti-GFP displayed a signiﬁ-
cant induction of locomotor activity after cocaine administration, with
a peak at 4100 mm ⁄min at 30 min (i.e. 10 min after drug
administration; Fig. 6A; upper row, right panel, ‘Session A (no
A
B
Fig. 4. Expression of a-synuclein in the NAcc from lentivirus-injected rats.
Animals were prepared as in Fig. 3. Proteins were extracted from the NAcc at
the end of each 5-day sessions of locomotor activity, as described in Materials
and methods. (A) Immunoblot of a-synuclein. Western blots, from gels loaded
with 15 lg protein ⁄ lane, were analysed for a-synuclein or 6-histidine
expression, and reprobed with anti-b-actin antibody to compare a-synuclein
expression in different lentivirus-injected rats. (B) Semi-quantitative analysis of
Western blot signals. a-Synuclein signals were estimated using multianalyst
software and normalized against the GAPDH signal. ***P < 0.001 a-synuclein
protein quantiﬁcation vs data from a-synuclein-injected rats without
doxycycline, +++P < 0.001 a-synuclein protein quantiﬁcation vs data from
a-synuclein-injected rats with doxycycline Two-way anova, Bonferroni
post hoc tests.
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dox)’). During Session B (i.e. animals fed doxycycline), the distance
travelled after cocaine injection was not signiﬁcantly altered, with a
peak at 5000 mm ⁄min at 30 min (Fig. 6A; middle row, right panel,
‘Session B (dox)’). Upon doxycycline removal (Session C), enabling
for GFP re-expression, the locomotor activity was similar to the other
sessions, with a peak at 4200 mm ⁄min at 30 min (Fig. 6A; lower
row, right panel, ‘Session C (no dox)’).
Animals infected with Lenti-aSyn displayed a signiﬁcant increase
(68%) in locomotor activity after cocaine administration, compared
with Lenti-GFP-treated animals, with a peak at 6800 mm ⁄min
observed 10 min after drug administration (Fig. 6A; upper row, left
panel, ‘Session A (no dox)’, F3,224 ¼ 236.1, P < 0.001). After 5 days
the same animals were fed doxycycline in the drinking water, inducing
a downregulation of exogenous lentivirus-expressed a-synuclein in the
NAcc. Two days after the doxycycline switch, behaviour upon chronic
cocaine administration was further monitored for ﬁve consecutive
days (Session B). The distance travelled after cocaine injection
displayed a peak at 5100 mm ⁄min at 30 min (Fig. 6A; middle row,
left panel, ‘Session B (dox)’), i.e. almost identical to levels observed
with Lenti-GFP-treated animals (P > 0.05, F3224 ¼ 688.36). After
5 days monitoring under this regimen, doxycycline was removed
(Session C), enabling re-expression of lentivirus-mediated a-synuclein
in the NAcc). Behaviour, measured 2 days later for ﬁve consecutive
days under these conditions, expressed a peak of locomotor activity at
Fig. 5. Immunohistochemistry of a-synuclein expression in the NAcc. Immunohistochemistry was performed after in vivo delivery of either: (a) Lenti-aSyn alone
(2 lL); (b) Lenti-aSyn (2 lL) combined with Lenti-aSyn-siRNAs (2 lL); (c) Lenti-aSyn-siRNAs (2 lL); or (d) Lenti-green ﬂuorescent protein (GFP; 2 lL).
Lentiviruses were injected into the NAcc according to the coordinates described in the Materials and methods. Animals used for behavioural analysis were fed either
5% sucrose or 5% sucrose ⁄ 0.02% doxycycline (see text for details). Animals were killed at the end of behavioural analyses; brains were dissected out and processed
for immunohistochemistry (see Materials and methods). Upper panels: expression of a-synuclein from animals fed 5% sucrose; lower panels: expression of
a-synuclein from animals under doxycycline treatment. (A) Sections were double-labelled using antibodies against a-synuclein (green) and NeuN (red), and
visualized by ﬂuorescence microscopy at 40 · magnitude. Lentiviral overexpression of a-synuclein shows an increase of a-synuclein (green) that is not co-localized
with the nuclei neurons labelling (red), but seems more likely expressed in neurites. (B) Sections were double-labelled using antibodies against a-synuclein (green)
and synaptophysin (red), and visualized by ﬂuorescence microscopy at 100 · magnitude. Yellow colour shows a large proportion of synaptic terminals co-expressing
a-synuclein and synaptophysin.
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 7300 mm ⁄min at 30 min (Fig. 6; lower row, left panel, ‘Session C
(no dox)’, F3,224 ¼ 544.33, P < 0.001). The difference between peaks
in Sessions A and C was not signiﬁcant (P > 0.2).
Another group, co-injected Lenti-aSyn and Lenti-aSyn-siRNAs,
was submitted to the same series of regimen and cocaine treatment.
In Session A, locomotor activity was signiﬁcantly lower than in the
previous group under the same conditions, with a peak at
 3100 mm ⁄min at 30 min (Fig. 6A; upper row, central panel,
‘Session A (no dox)’, P < 0.001 as compared with a-synuclein-
treated group, F3,224 ¼ 236.12). In Session B, locomotor activity
slightly decreased, with a peak of  2900 mm ⁄min at 30 min
(Fig. 6A; middle row, central panel, ‘Session B (dox)’; P < 0.001 as
compared with a-synuclein-treated group; F3,224 ¼ 688.36). Under
these conditions, downregulation of exogenous, lentivirus-mediated
a-synuclein expression is achieved, together with knockdown of
endogenous (cocaine-induced) expression. The observed residual
behavioural activity is about 30% lower than in corresponding GFP-
treated animals, as in the absence of a-synuclein-speciﬁc siRNAs,
synuclein would be strongly induced by cocaine under these
conditions. In Session C, when doxycycline has been removed from
water on the same animals, enabling full expression of the ectopic a-
synuclein in the NAcc, the locomotor activity drops to the basal
level, reaching levels comparable to the ﬁrst session
( 3000 mm ⁄min 15 min after cocaine delivery; Fig. 6A; lower
row, central panel, ‘Session C (no dox)’, P < 0.001 as compared
with a-synuclein-treated group, F3,224 ¼ 544.33).
The last group of animals, infected only with Lenti-aSyn-siRNAs
to assess effects of endogenous a-synuclein, displayed very low
locomotor activity  1700 mm ⁄min at 30 min in the absence of
doxycycline (Fig. 6A; upper row, right panel, ‘Session A (no dox)’,
P < 0.001, F3,224 ¼ 236.12 as compared with a-synuclein-treated
group). In Session B, i.e. when switched to the doxycycline
regimen, no signiﬁcant change was observed, with a peak of
 2600 mm ⁄min at 30 min (Fig. 6A; middle row, right panel
‘Session B (dox)’, P < 0.001 as compared with a-synuclein-treated
group, F3,224 ¼ 688.36). Upon doxycycline removal, 5 days later,
locomotor activity peaked at  2000 mm ⁄min (Fig. 6A; lower row,
right panel, ‘Session C (no dox)’, P < 0.001 as compared with a-
synuclein-treated group, F3,224 ¼ 544.33). The observed difference
between these three sessions within this group of animals was not
signiﬁcant (P > 0.2). These observed behavioural effects were
highly correlated with changes of a-synuclein, as veriﬁed at protein
levels by means of Western blot analysis (Fig. 4) and immunohis-
tochemistry (Fig. 5).
Fig. 6. (A and B) In vivo effects of a-synuclein overexpression or silencing in the NAcc on cocaine-induced locomotor activity. Values represent means ± SEM of
5 days (n ¼ 8). One week after surgery, chronic cocaine delivery was started and locomotor activity was monitored. At each daily session, animals received saline
injections before the habituation period (15 min) followed by cocaine delivery (i.p. 15 mg ⁄ kg), and the locomotor activity was monitored immediately after drug
injection. Overexpression of a-synuclein in the NAcc induced a signiﬁcant increase on cocaine-induced locomotor activity that could be abolished by doxycycline
treatment. Silencing of a-synuclein lead to a decrease of cocaine-induced locomotor activity. *P < 0.05, **P < 0.01 and ***P < 0.001, vs data from Lenti-green
ﬂuorescent protein (GFP)-infected rats; ##P < 0.01 and ###P < 0.001 vs data from Lenti-asyn-injected rats, two-way anova, Bonferroni post hoc tests.
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Drug-induced behavioural sensitization was observed during Ses-
sion A for all groups, over the ﬁve initial days (Fig. 7). Sensitization is
highest in the Lenti-GFP-treated animals, which display a 63%
increase in locomotor activity over this session, vs about 15% increase
in a-synuclein-overexpressing animals (P < 0.001, F2,48 ¼ 10.52).
Silencing a-synuclein raises this effect, to values close to GFP-treated
animals. During subsequent Sessions B and C, further sensitization
could not be observed signiﬁcantly (P > 0.05, F6,48 ¼ 5.24).
Changes in SA upon a-synuclein expression
Three groups of animals (n ¼ 8) were used to test the effects of
a-synuclein expression in the NAcc on the cocaine SA paradigm
(Fig. 7). One group was injected with the doxycycline regulatable
Lenti-aSyn, a second group was co-injected with Lenti-aSyn and
Lenti-aSyn-siRNAs, and a third group was injected with the
doxycycline regulatable Lenti-GFP and served as a control group.
Animals were trained for SA, then operated, as described in the
Materials and methods. Data are presented in Fig. 8.
GFP-injected animals demonstrated a strong SA behaviour under a
FR5 schedule of reinforcement with a mean of 15.5 infusions per
session. After 5 days, the same animals were fed with doxycycline in
the drinking water. During two consecutives days, animals could SA
cocaine, but behaviour was not measured in order to achieve a full
doxycycline switch of a-synuclein expression before measurements.
Thereafter, SA was further monitored for ﬁve consecutive days under
doxycycline (Session B). Under these conditions the number of
infusions was unchanged, with a mean at 15.2 per session.
The second group, injected with Lenti-aSyn and overexpressing of
a-synuclein in the NAcc, displayed a strong increase in SA of cocaine
during Session A, with a mean of 30 infusions per session, i.e. a 1.9-
fold increase over the control GFP group (F2,180 ¼ 745.64,
P < 0.001). After 5 days, animals were fed doxycycline (Session B),
suppressing a-synuclein overexpression, and SAwas measured 2 days
later for ﬁve consecutive days. Under these conditions, the number of
cocaine self-infusions dropped to 18.2 per session (P > 0.05).
The third group of animals ) co-injected with Lenti-a-Syn and
Lenti-aSyn-siRNAs ) displayed a mean of 12.2 infusions per session
in Session A, not signiﬁcantly different from the control group
(P > 0.05). Doxycycline treatment switches off Lenti-aSyn but not
Fig. 7. Drug-induced behavioural sensitization. Animals used for behavioural analysis were fed either 5% sucrose or 5% sucrose ⁄ 0.02% doxycycline (see text for
details). Values represent means ± SEM of peak locomotor activity from one group of animals (n ¼ 8) each day. One week after surgery, chronic cocaine delivery
was started and locomotor activity was monitored (see Fig. 6). After ﬁve consecutive days of drug delivery, animals were fed doxycycline and measured 2 days after
the switch for another period of ﬁve consecutive days. Then the regimen was switched back (no doxycycline) and, 2 days after the second switch, was measured for
5 days.
Fig. 8. Effects of a-synuclein on cocaine SA under ﬁxed ratio (FR)5 schedule
of reinforcement. Each histogram represents the means of dose–response for
ﬁve consecutive days (n ¼ 8). SA was performed for ﬁve consecutive days in
the presence of doxycycline in the drinking water (Session A); then
doxycycline was removed (Session B). Overexpression of a-synuclein in the
NAcc results in a signiﬁcant increase in the number of cocaine SA. This change
could be abolished by doxycycline treatment. **P < 0.01 vs data from Lenti-
GFP-infected rats; ##P < 0.01 and ###P < 0.001 vs data from a-synuclein-
injected rats, two-way anova, Bonferroni post hoc tests. Results show an
increase in numbers of cocaine self-infusions in animals injected with Lenti-
a-Syn as compared with the Lenti-green ﬂuorescent protein (GFP)-injected
group (###P < 0.001) and with the Lenti-aSyn + Lenti-aSyn-siRNAs-injected
group. Therefore, after doxycycline treatment, animals injected with Lenti-
aSyn still display a signiﬁcant increase in numbers of cocaine self-infusions as
compared with Lenti-aSyn + Lenti-aSyn-siRNAs rats (##P < 0.01).
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Lenti-aSyn-siRNAs, resulting both in a suppression of lentivirus-
mediated a-synuclein overexpression as well as in silencing endo-
genous a-synuclein expression. Under these conditions (Session B),
animals displayed a very high decrease in cocaine SA, with a mean of
6.2 infusions per session. This represents a 40.8% (F2,180 ¼ 745.64,
P < 0.01) and 34.1% (F2,180 ¼ 745.64, P < 0.01) decrease in the
number of cocaine self-infusion, compared with the GFP control
group and the a-synuclein-injected group, respectively, under the same
conditions.
Discussion
In the present study we aimed at establishing a causal relationship
between alterations in a-synuclein levels and cocaine-induced
behaviours. To this end, we have developed inducible lentiviral
tools that very efﬁciently enable to locally alter a-synuclein levels,
and studied the consequences of varying a-synuclein levels on
cocaine-induced locomotion and SA. In previous studies we showed
that cocaine administration induces a strong increase of a- and
c-synucleins in the NAcc (Brenz-Verca et al., 2003). This was
corroborated in the present study: upon cocaine administration,
a-synuclein mRNA in GFP-treated animals is induced 3.1-fold in
the NAcc, compared with naı¨ve, saline control animals. There is
correlative evidence in humans that cocaine abusers overexpress
a-synuclein in dopaminergic neurons, mainly in the VTA and
substantia nigra (Mash et al., 2003).
In this study we present evidence that an increase in a-synuclein
expression strongly correlates with behavioural changes observed
under different drug administration paradigms. Our data clearly show
a differential effect of overexpression and siRNA conditions with
locomotion correlating with expression level. Local overexpression
of a-synuclein in the NAcc rapidly induces increased locomotor
response to cocaine and increased SA of the drug, both effects that
can be fully reversed in the presence of doxycycline. Furthermore,
selective knockdown of a-synuclein in the NAcc also strongly
affects both locomotor activity and SA. Behavioural effects strongly
correlate mRNA and protein expression of a-synuclein in this brain
area. This suggests that a-synuclein expression in the NAcc plays an
important role in cocaine-mediated behaviour. Behavioural changes
have been compared with GFP-treated animals, as previous studies
established that GFP does not affect behaviour in the paradigms
under investigation (Bahi et al., 2004a,b). In addition, saline-treated
animals were used as control, showing that cocaine indeed has some
effects on a-synuclein mRNA levels in the NAcc. The increased SA
of cocaine suggests that enhanced expression of a-synuclein makes
the animals less sensitive to cocaine. The reinforcing properties of
cocaine appear to have decreased, as suggested by the increased
number of self-infusion, thus a-synuclein overexpression may induce
reduced cocaine reinforcement. The animals are compensating for
the decreased effect by taking more drug. Therefore, increased
a-synuclein expression in the NAcc may result in enhanced
locomotion induced by cocaine, but decreased reinforcing properties
of the drug. On the other hand, our studies have so far been limited
to single dose injection, and no dose–effect responses have been
performed in the present study. Thus, it is also possible that
a-synuclein expression in the NAcc induces a rightward shift in the
dose–effect curve. Shifts in dose–injection curves may reﬂect reward
allostasis, not sensitization (Ahmed & Koob, 2004), and escalated
drug intake may often be suggestive of a negative reinforcement due
to allostatic decrease in reward function (Ahmed & Koob, 1999,
2005). Further studies at different doses may clarify this.
Interestingly, changes in a-synuclein expression result in apparent
cocaine-induced sensitization in the ﬁrst sessions (Session A), but no
more in Sessions B and C. However, the absence of sensitization in
synuclein knockdown animals could be interpreted as the results of a
ceiling effect. The level of cocaine-induced locomotion may then be
so high already on the ﬁrst exposure that there are no further
possibilities for a further increase. As a matter of fact, cocaine-induced
sensitization cannot be reversed on the very same animal fed
doxycycline, then upon doxycycline removal. On the other hand,
behavioural sensitization can arise from neuroadaptations in multiple
brain nuclei (Vanderschuren & Kalivas, 2000), and our data could
rather reﬂect the differential involvement of the accumbens vs other
brain regions in the expression or induction of cocaine sensitization.
Indeed, cortical and allocortical brain regions such as the prefrontal
cortex appear to be more critical for cocaine sensitization.
It has been established that cocaine abuse elevates a-synuclein and
DAT levels in the human striatum (Qin et al., 2005). In addition,
a-synuclein interactions with the DAT mediate the reuptake of DA
released into the synaptic cleft by DA-producing neurons (Perez &
Hastings, 2004; Vekrellis et al., 2004; Wersinger & Sidhu, 2005). This
interaction regulates dopaminergic content, neurotransmission and
synaptic strength at dopaminergic terminals (Zhou et al., 2002). Studies
in a-synuclein knockout mice revealed that it might inhibit reﬁlling and
reduce the storage capacity of presynaptic DA-containing vesicles, thus
serving as a negative regulator of dopaminergic neurotransmission
(Abeliovich et al., 2000; Yavich et al., 2004). a-Synuclein exerts
modulatory effects on DAT function, as well as on tyrosine hydroxy-
lase activity, the rate-limiting enzyme in DA biosynthesis (Clayton &
George, 1999; Perez et al., 2002), and on vesicular storage of DA
(Ueda et al., 1993; Akopian & Wood, 1995). This would imply that a
primary normative function of a-synuclein in DA-producing neurons
might be the regulation and maintenance of DA homeostasis (Neystat
et al., 1999; Lotharius et al., 2002). The high concentration of
synucleins in presynaptic terminals suggested an essential role for
synucleins in synapse formation, neurotransmitter release or synaptic
plasticity (Clayton & George, 1998). As a matter of fact, our data may
strongly support this view, as changes in its expression in the NAcc
strongly affects reward, a process essentially related to DA release in
this brain area. In our study, viral injection was performed into the
NAcc. Lentiviruses being replication incompetent and self-inactivat-
ing, they will not spread away from the injected area.
Because of its high levels and its role in dopaminergic pathways, it
has been suggested that a-synuclein could be potentially involved in
the effects exerted by psychostimulants on the dopaminergic reward
pathway. a-Synuclein mRNA regulation by chronic morphine admin-
istration in the mouse amygdala, a target region of dopaminergic
projection, plays an essential role in reinstatement of opiate-reinforced
behaviours (Sutcliffe et al., 2000; Fuchs & See, 2002; Shalev et al.,
2002). On the other hand, mice withdrawn from chronic morphine
treatment display downregulation of a-synuclein mRNA in the NAcc
and related brain areas, e.g. the basolateral amygdala, the dorsal
striatum and the VTA (Ziolkowska et al., 2005), in agreement with the
observation reported in our present study for chronic cocaine. The
changes were the most pronounced after longer periods of withdrawal,
and were signiﬁcantly increased in the striatum ⁄ accumbens for as long
as 2 weeks after treatment cessation (Ziolkowska et al., 2005).
Synucleins are not essential for basic synaptic functions (e.g.
neurotransmitter release, synaptic vesicle numbers and pools, and
synaptic plasticity), but are redundantly required for maintaining
normal DA levels in the nigrostriatal system (Chandra et al., 2004).
No major phenotype was observed in a-synuclein knockout mice
(Abeliovich et al., 2000). A confounding problem in studying
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a-synuclein is the presence of b- and c-synucleins, highly homologous
isoforms (Ueda et al., 1993; Akopian & Wood, 1995; George et al.,
1995; Ji et al., 1997). The a- and b-synucleins are widely co-localized
in presynaptic nerve terminals throughout the brain, but absent from
peripheral tissues (Maroteaux et al., 1988). In contrast, c-synuclein is
abundant in specialized neurons, such as dorsal root ganglia (Akopian
& Wood, 1995; Murphy et al., 2000), and in non-neuronal tissues or
certain tumour cells (Ji et al., 1997; Buchman et al., 1998; Surguchov
et al., 1999). The high degree of co-expression of a- and b-synuclein
indicates the potential for functional redundancy, which may have
obscured an essential role of a-synuclein in a-synuclein knockout
mice. The tools we have developed circumvent these difﬁculties, and
enable for very local gene transfer and very local changes of gene
expression. Because a-synuclein is described as a widely presynaptic
protein, the cocaine-mediated changes in mRNA and protein levels
that we report in this study are likely to take place in the same
populations of projection neurons. Axonal localization of a-synuclein
was conﬁrmed by immunoﬂuorescent labelling. Other studies,
however, described further increased mRNA expression in response
to, e.g. morphine in distinct populations as well, whose somata are in
different brain areas (Ziolkowska et al., 2005).
From our studies, a role for a-synuclein in addiction to cocaine
may clearly be postulated. However, addiction refers to a speciﬁc
pattern of compulsive drug-seeking and drug-taking behaviour, one
that predominates over most other activities in life (Robinson, 2004;
Vanderschuren & Everitt, 2004). Deroche-Gamonet clearly identiﬁed
addiction as the result from the interaction of two variables
(Deroche-Gamonet et al., 2004): (i) the degree of exposure to drugs
(because addiction-like behaviour appears only after extended access
to cocaine); and (ii) the degree of vulnerability in the exposed
individual (because, despite a similar drug intake in all subjects,
addiction-like behaviour appears only in a few). It is the interaction
between a long exposure to drug and a vulnerable phenotype, not
one or the other factor in itself, that seems to determine the
development of addiction. The vulnerable phenotype greatly depends
on local drug-mediated expression changes of a very large array of
genes, as addiction is largely a multigenetic brain disorder. A sound
characterization of the role of the different genes regulated upon
addiction, as exempliﬁed with the highly speciﬁc tools developed in
this study for a-synuclein, is therefore essential for understanding the
molecular mechanisms involved in this process. Our results demon-
strate that a-synuclein is able to modulate cocaine-induced behavio-
ural effects. This suggests that targeting a-synuclein function could
provide new therapeutic strategies to treat cocaine abuse for which
there is no available treatment.
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Fig. S1. Immunohistochemistry of a-synuclein and NeuN expression
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